TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

By sjmartinez • April 30, 2024

Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. PMID: 38686016; PMCID: PMC11057345.

Tags: adjuvant therapy, antibody–drug conjugates, Hematology/Oncology, immunotherapy, Programmed cell death ligand-1, Publications, triple-negative breast cancer, trophoblast cell-surface antigen 2

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui[...]

Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report

Young P, Kroloff M. Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report. Cureus. 2025 Oct 21;17(10):e95064. doi:[...]

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy

Duesberg MS, Schiller G. Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy. Cureus. 2025 Oct 21;17(10):e95112. doi: 10.7759/cureus.95112. PMID: 41281092;[...]